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Abstract 
Background: Fampridine improves walking in patients with multiple sclerosis (pwMS). However, little is known 
about its impact on the quality of life (QoL) of pwMS.
Objectives: This study aimed to evaluate the contribution of fampridine on the QoL of pwMS and to determine if 
improvements in QoL are best associated with walk respondents.
Methods: Fifty pwMS were included in this study. The PERSEPP scale and the GaitRite system were used to evaluate 
QoL and gait respectively. QoL was evaluated 7 days before fampridine (Pre1), on the day the fampridine treatment 
was initiated (Pre2), and 14 and 21 days after fampridine (Post1 and Post2 respectively). Gait was assessed at Pre-1, 
Pre-2 and Post-1.
Results: For all patients, fampridine had significant effects (p = 0.05–10−4, d = 0.25–0.45) on the Overall, Relationship 
difficulties, Fatigue, Time perspective and Symptoms QoL indices and for gait parameters (p = 0.05–10−4, d = 0.17–0.38). 
Non-respondents scored significant effects (p < 0.05–0.01, d = 0.32–0.41) for Overall, Time perspective and Symptoms 
QoL indices, whereas respondents scored significant effects (p < 0.05–0.01, d = 0.51–0.8) for Overall, Relationship dif-
ficulties, Fatigue and Symptoms.
Conclusion: The QoL of pwMS improved after fampridine, suggesting a real benefit in their lives. However, the con-
tributions to the overall QoL index seem different between groups.
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Background
Multiple sclerosis (MS) is a chronic neurological disorder 
affecting young and middle-aged adults with a female to 
male ratio of more than 3:1 (Compston and Coles 2008). 
The cause of MS is unknown although it involves genetic 
susceptibility and environmental exposure (Compston 
and Coles 2008). Since there is no known cure for MS, 
the main goals of treatment is to delay progression of 
the disease and to improve health-related quality of life 
(HRQoL) by masking patients’ symptoms (Compston and 
Coles 2008).
Among several symptoms of MS (e.g., motor and cog-
nitive impairments, optic neuritis, fatigue, pain, urinary 
dysfunction) (Smith and McDonald 1999), walking dis-
turbance is traditionally one of the most important and 
have been used as a major criterion to assess the progres-
sion of the disease [e.g., the expanded disability status 
scale (EDSS) developed by Kurtzke (1983)]. Studies have 
reported that approximately 75 % of individuals with MS 
experience clinically significant walking disturbances and 
this applies even to those with mild EDSS scores (from 
1 to 3.5) (Bethoux and Bennett 2011; Johansson et  al. 
2007). Moreover, walking is related to several daily activi-
ties, social participation and independence of individuals 
(Bethoux and Bennett 2011).
Studies have shown that MS symptomatic treatment 
by fampridine (4-aminopyridine) is associated with 
improvements in walking and muscle strength (Allart 
et al. 2015; Rabadi et al. 2013; Hobart et al. 2013; Good-
man et  al. 2009, 2010), and possibly with cognition 
(Jensen et  al. 2014), vision, fatigue and spasticity (for 
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a review see Jensen et al. 2014). Indeed, fampridine is a 
potassium channel blocker which reduces the leakage of 
ionic current through these channels, prolonging repolar-
ization and thus, enhancing action-potential formation in 
demyelinated axons (Targ and Kocsis 1985). Presumably, 
by enhancing action-potential formation, more impulses 
might be conducted in the central nervous system (CNS) 
and neurological functions could be ameliorated (Jensen 
et al. 2014; Hayes et al. 2004). In recent phase III studies, 
Goodman et al. (2009, 2010) investigated the fampridine 
effect on the walk of individuals with MS during a timed 
25-foot walk test (T25FW). Improvement in walking 
velocity (≈25 % from baseline) was found for 35–43 % of 
the individuals in the interventional group.
Regarding determining factors related to HRQoL, 
mobility was given the highest priority by 65  % of indi-
viduals with MS (Bethoux and Bennett 2011). Functional 
disability measured by patients (i.e., using the Incapacity 
Status Scale) was significantly associated with both phys-
ical and mental component scales from a generic HRQoL 
questionnaire (i.e., short form-36 health survey) (Gav-
elova et al. 2015). HRQoL has been defined as subjective 
satisfaction with life (Schwartz and Frohner 2005). This 
concept, besides what most people intuitively under-
stand, is difficult to define precisely. It seems important 
as traditionally used measures of medical outcomes do 
not sufficiently capture the full impact of the medical 
intervention in the individuals’ lives (Schwartz and Froh-
ner 2005), and this is especially true in the case of chronic 
and multidimensional diseases such as MS. However, 
the fampridine effect on other clinical symptoms of MS 
as well as on HRQoL measured with MS-specific instru-
ments has not been extensively researched, with studies 
limiting themselves in most cases to gait (Jensen et  al. 
2014).
The evaluation of the fampridine effect in terms of gait 
and HRQoL should bring new insights into its direct 
and indirect role in individuals with MS. Therefore, this 
study proposed (1) to evaluate the contribution of fam-
pridine in the HRQoL of individuals with MS and (2) to 
determine if improvements in HRQoL are more impor-




In an open-label study design, 50 patients with MS 
were included. All patients met the following inclusion 
criteria: (1) MS diagnosis regarding the modified Mc 
Donald criteria (Polman et  al. 2011); (2) EDSS status 
between 4.0 and 6.5; and (3) patients able to walk for at 
least 6  min. The exclusion criteria were: (1) worsening 
MS symptoms during the previous 60 days; (2) history 
of epilepsy or epileptic seizures; (3) immunotherapy 
change in the previous 60  days; (4) beginning anti-
spastic treatment in the previous 30 days; (5) initiation 
of treatment able to decrease fatigue symptoms in the 
previous 30 days; (6) modification of the rehabilitation 
program during the study; (7) renal insufficiency (cre-
atinine clearance <80 ml min−1 given by the Kockroft-
Gault formula); (8) concomitant treatment by organic 
cation transporter 2 inhibitor; and (9) hypersensitivity 
to fampridine. Patients’ characteristics are shown in 
Table 1.
The study was approved by the ethics committee of 
the University Hospital of Besançon (n. 13/405) and 
the French National Security Agency of Medicines and 
Health Products (ANSM 2013-A002305-56). Written 
informed consent was obtained from all patients.
HRQoL evaluation
The PERSEPP scale (PERception de la Sclérose En Plaques 
et de ses Poussées) was used to evaluate the HRQoL of 
patients with MS (Baroin et  al. 2013). This scale takes 
into account several aspects of HRQoL distributed across 
66 items (described below) and includes relapse phases.
Each item contains 6 response types according to a Lik-
ert scale where “0” was “strongly disagree” and “5” was 
“strongly agree”. The PERSEPP scale has been validated 
in the French language and has a good acceptability (non-
return rate <10 %), construct validity (Cronbachs’ α > 0.7) 
and reliability (ICC: 0.72–0.92) (Baroin et al. 2013).
The 10 PERSEPP indices described below were taken 
into account for this study. First of all, the Overall (33 
items) and the Relapse (15 items) indices were calcu-
lated. Five indices from the 5 dimensions which compose 
the Overall index were also calculated: Social support (5 
items), Relationship difficulties (work, family and with 
Table 1 Means and  (SD) of  patients’ characteristics 
at baseline
The italic value correspond statistical significant differences
EDSS expanded disability status scale, BMI body mass index, RR relapsing–
remitting, SP secondary progressive, PP primary progressive
Patients’ char-
acteristics








Age (years) 51.4 (11.7) 49.2 (10.9) 55.5 (12.3) 0.06
Gender (m/f %) 32/68 30/70 35/65 0.45
EDSS 5.2 (1.1) 5 (1.0) 5.8 (1.1) 0.01
Height (m) 1.67 (0.09) 1.67 (0.09) 1.66 (0.08) 0.66
Body mass (kg) 75.5 (17.2) 73.1 (16.9) 80.12 (17.4) 0.17
BMI (kg m−2) 27 (5.7) 26 (5.7) 28.9 (5.5) 0.09
Disease duration 
(years)
14.3 (9.3) 13.5 (8.5) 16.2 (11) 0.36
MS type (RR–
SP–PP %)
22–48–32 22–49–29 13–47–40 0.22
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partner) (9 items), Fatigue (4 items), State of mind and 
associated sleep disorders (7 items) and Time perspec-
tive (8 items). To finish, 3 indices from the 3 modules 
proposed by PERSEPP were evaluated: Coping (8 items), 
Symptoms (20 items) and Treatment (5 items). Each 
PERSEPP index was transformed to a range of 0–100 
with high values indicating an improved level of HRQoL 
in a particular dimension.
Gait evaluation
The gait evaluation was carried out in a dedicated room 
with the GaitRite system (CIR System Inc., USA), an 
instrumented walkway embedded with pressure sensors 
sampled at 120 Hz. The active gait recording surface was 
6.10  ×  0.61 meters. After appropriate instructions and 
familiarization, patients were asked to walk with stand-
ard sports shoes provided by our laboratory at a fast 
speed condition (Coleman et al. 2012). To produce a rep-
resentative gait pattern, a minimum of 10 gait cycles were 
recorded for each patient. Spatiotemporal gait param-
eters determined by averaging values across these gait 
cycles were gait velocity (m s−1), cadence (steps min−1), 
step length (m), step time (s), step width (m), stance time 
(% of gait cycle) and double support time (% of gait cycle).
Procedures
This study was realized in the Laboratory of Clinical 
Functional Exploration of Movement at the University 
Hospital of Besançon. HRQoL was assessed at 4 inter-
vals: 7  days before fampridine treatment initiation (Pre 
1); on the day, but before the fampridine treatment ini-
tiation (Pre 2); and 14 and 21 days after fampridine treat-
ment initiation, respectively Post 1 and Post 2.
Gait was assessed 3 times at Pre 1, Pre 2 and Post 1. 
Indeed, fampridine was prescribed according to the 
guidelines issued by the French National Security Agency 
of Medicines and Health Products (ANSM) at the dose 
of 10  mg twice a day. Fampridine is indicated for the 
improvement of walking in MS patients with a walking 
disability (EDSS between 4 and 7). According to official 
ANSM guidelines, the prescription is initially limited to 
2  weeks of therapy, at which point a new assessment is 
performed by the medical practitioner to evaluate the 
clinical benefits. If no improvement is observed, fampri-
dine should be discontinued.
According to the gait velocity evolution (%) between 
Pre 1 and Post 1 (i.e., before 14  days after fampridine 
treatment as recommended by the ANSM), patients were 
then classified into two groups: respondents whose gait 
velocity improved (in the fast condition) by over 25  % 
related to the baseline and non-respondents whose gait 
velocity did not improve by over 25 %. This conservative 
threshold corresponds to the average improvement that 
was maintained throughout the treatment period in the 
Goodman et al. (2009) study.
Statistical analysis
Data management and analyses were performed using 
Statistica version 10 (StatSoft., USA). The results were 
expressed as mean and standard deviation (SD). 1-way 
analysis of variance for repeated measurements was used 
to analyze HRQoL and gait evaluations of all patients 
after checked normality and homogeneity of variances.
To compare respondent and non-respondent groups 
(between-factor) during the evaluations (within-factor) 
in terms of HRQoL and gait, a 2-way analysis of vari-
ance was performed. Only the main effects (i.e. the group 
effect and the fampridine effect) were considered in this 
study. Tukey post hoc tests were conducted when sig-
nificant effects existed. This test took into consideration 
the correction necessary for our 4 evaluations (3 evalu-
ations for the gait) and thus, the level of significance was 
preserved at 0.05 for all analyses. In addition, effect sizes 
were calculated to evaluate if differences observed for 
HRQoL and gait parameters corresponded to important 
clinical effects (Cohen 1988). The effect size (d) is defined 
as the mean unadjusted difference divided by the pooled 
standard deviation of the corresponding mean scores. 
Effect sizes of 0.2, 0.5 and 0.8 were regarded as small, 
medium and large degrees of differences, respectively.
Results
All participants
Table 1 shows the participants’ characteristics as well as 
those categorized as non-respondent (n = 35, 70 %) and 
respondent groups (n = 15, 30 %) according to the Good-
man et  al. (2009) gait velocity threshold. No differences 
were found between the groups’ characteristics except 
for the EDSS score. The respondent group had a more 
important EDSS score than the non-respondent group 
[EDSS mean (SD): respondent 5.8 (1.5) vs. non-respond-
ent 5 (Compston and Coles 2008); p = 0.01, d = 0.8].
Regarding the results of all patients for the HRQoL 
indices, fampridine was found to have significant medium 
effects (p  =  0.05–10−4, d  =  0.25–0.45) for the follow-
ing HRQoL indices: Overall, Relationship difficulties, 
Fatigue, Time perspective and Symptoms (Table  2). No 
significant differences were found between the two con-
ditions before (Pre 1 vs. Pre 2) and after fampridine (Post 
1 vs. Post 2), except for the Treatment index (p = 0.001, 
d = 0.5) which was more important at Post 2 than at Post 
1 (Table 2).
In terms of spatiotemporal gait parameters, consid-
ering all patients, significant small to medium effects 
(p = 0.05–10−4, d = 0.17–0.38) were found after fampri-
dine (Table  3). For all patients, gait improvement from 
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baseline was comprised between 2.6 % (stance time) and 
14 % (velocity).
Non-respondents and respondents
Table  4 shows the same spatiotemporal gait parameters 
presented above but categorized as non-respondent 
and respondent groups. For the non-respondent group, 
when comparing pre- and post-fampridine treatment, 
significant small effects (p  <  0.05, d  =  0.12–0.22) were 
found for step length, stance time and double support 
time without an improvement in gait velocity. These gait 
improvements were comprised between 1.2 and 3.6  % 
from baseline. For the respondent groups, except for 
step width, all parameters presented significant medium 
to large effects (p = 10−3–10−4, d = 0.45–0.9). In terms 
of gait velocity, improvements after fampridine ranged 
between 31  % (Pre 2 vs. Post 1) to 56  % (Pre 1 vs. Post 
1) from baseline values. The respondent group also pre-
sented significant small differences (p  =  0.05–10−3, 
d = 0.03–0.06) comparing the two pre-intervention con-
ditions for gait velocity, cadence and step length. This 
differences, comprising between 5.6 and 19.2  %, were 
however lower than those found after fampridine treat-
ment (Table 4).
To finish, the analysis of HRQoL for non-respondent 
and respondent groups found that the non-respondent 
group scored significant medium effects after fampri-
dine (p  <  0.05–0.01, d  =  0.32–0.41) for Overall, Time 
perspective and Symptoms indices (Table  5). Differences 
were comprised between 2 and 9 percentage points. The 
respondent group scored significant medium to large 
effects after fampridine (p < 0.05–0.01, d = 0.51–0.8) for 
the indices: Overall, Relationship difficulties, Fatigue and 
Symptoms. Differences were comprised between 4 and 22 
percentage points.
As expected, the non-respondent and respondent 
groups were significantly different for all spatiotempo-
ral gait parameters (p  <  0.01) independent of evalua-
tions (within-factor), except for step width. However, 
significant differences between the non-respondent and 
respondent groups were neither found for HRQoL indi-
ces nor for the progression (i.e., percentage of mean 
improvement between Pre 1 and Post 2) of the Overall 
index.
Discussion
Even if walking disorders are considered the main symp-
toms of patients with MS, it is well recognized that they 
do not reflect all the facets that patients consider impor-
tant in their life. Fatigue, relationship difficulties or sleep 
disorders are many other examples of a person’s experi-
ence with MS. These symptoms could be influenced by 
walking disorders which in turn could be treated by fam-
pridine (as per the ANSM guidelines) and thus assessed 
by specific HRQoL and spatiotemporal gait parameters.
Therefore, the aim of this study was to explore the 
short-term effects of fampridine in the HRQoL of 
patients with MS and then to determine if the so-
called walking respondents seem to better benefit from 
Table 2 Mean and  (SD) of  the different indices of  the 
PERSEPP HRQoL questionnaire for all patients before (Pre 
1 and Pre 2) and after (Post 1 and Post 2) fampridine
The italic values correspond statistical significant differences
* p 10−4 Pre 1 and Pre 2 versus Post 2
** p < 0.01 Pre 1 versus Post 2
*** p < 0.05 Pre 1 and Pre 2 versus Post1 and Post 2
+  p < 0.01 Pre 1 and Pre 2 versus Post 2
† p < 0.05 Pre 1 and Pre 2 versus Post 1, and p: 10−4 Pre 1 and Pre 2 versus Post 2
¥  p: < 10−3 Post 1 and Post 2
PERSEPP (%)  
(items)
All patients (n = 50)
Pre 1 Pre 2 Post 1 Post 2
Overall (33) 62.4 (16.4) 62.5 (16.9) 66.3 (17.6) 68.9 (18.4)*
Social support (5) 87.2 (14.2) 86.5 (16.4) 87.5 (16.7) 88.2 (17)
Relationship dif. (9) 52.2 (22.8) 54.7 (24.1) 59 (24.5) 61.9 (23.2)**
Fatigue (4) 43.5 (30.9) 44 (29.2) 52.4 (32.8)*** 52.8 (34.7)***
State of mind and 
sleep disorder (7)
63.2 (24.8) 64.3 (26.9) 67.5 (26.6) 69.5 (27.2)
Time perspective 
(8)
59.2 (22) 57.5 (21.8) 62.4 (24.5) 66.6 (23.5)+
Relapse (15) 
(n = 29)
48.4 (24.4) 50.6 (23) 53.4 (24) 55.7 (28.2)
Modules
Coping (8) 58.7 (19.1) 58.1 (19.) 59.6 (21) 59.5 (20.6)
Symptoms (20) 54.6 (17.9) 55.1 (18.6) 59.5 (17.7)† 63 (18.8)†
Treatment (5) 
(n = 26)
86.5 (15.7) 78.6 (25) 80.9 (18.1) 88 (13.8)¥
Table 3 Mean and (SD) of spatiotemporal gait parameters 
for  all patients before  (Pre 1 and  Pre 2 and  after (Post 1) 
fampridine
The italic values correspond statistical significant differences
* p < 0.05 Pre 1 and Pre 2 versus Post 1
** p 10−3 Pre 1 and Pre 2 versus Post 1




Pre 1 Pre 2 Post 1
Velocity (m s−1) 1.05 (0.49) 1.08 (0.51) 1.2 (0.48)**
Cadence (steps min−1) 105.18 (28.74) 106.57 (28.98) 112.79 (24.9)**
Step length (m) 0.57 (0.17) 0.58 (0.18) 0.62 (0.16)**
Step time (s) 0.63 (0.25) 0.62 (0.22) 0.56 (0.16)**
Step width (m) 0.13 (0.05) 0.13 (0.05) 0.12 (0.04)*
Stance time (% GC) 66.03 (5.39) 65.83 (5.6) 64.13 (4.51)£
Double supp. time (% GC) 32.53 (10.84) 31.91 (11.27) 29.06 (8.23)£
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fampridine treatment in terms of HRQoL. First of all, our 
results pointed out that fampridine can improve HRQoL 
in patients with MS as well as their gait. Secondly, con-
trary to what we could expect, HRQoL improved in both 
non-respondent and respondent groups. However, for 
the same rate of overall improvement in HRQoL in both 
groups, the HRQoL sub-indices that showed significant 
improvement after treatment were different between the 
two. This suggests that, as fampridine acts primarily on 
neurological function, benefits could be perceived differ-
ently in groups with different motor impairments.
Previous studies suggest that, based exclusively on walk-
ing velocity, only some patients respond with clear clini-
cal benefits to fampridine treatment (Goodman et  al. 
2009, 2010; Jensen et  al. 2014). Using the same protocol 
and parameter (i.e., walking velocity at fast condition), 
Table 4 Mean and (SD) of the spatiotemporal gait parameters for the non-respondent and respondent groups at Pre 1, 
Pre 2 and Post 1
The italic values correspond statistical significant differences
†  p < 0.05 Pre 1 versus Post 1
* p < 0.05 Pre 1 versus Pre 2
** p < 0.01 Pre 1 versus Pre 2
*** p 10−3 Pre 1 and Pre 2 versus Post 1
£  p 10−4 Pre 1 and Pre 2 versus Post 1
Spatiotemporal gait parameters Non-respondent (n = 35) Respondent (n = 15)
Pre 1 Pre 2 Post 1 Pre 1 Pre 2 Post 1
Velocity (m s−1) 1.21 (0.44) 1.2 (0.48) 1.27 (0.46) 0.66 (0.36) 0.78 (0.48)* 1.03 (0.51)£
Cadence (steps min−1) 115.11 (23.03) 113.29 (25.98) 116.35 (23.83) 82.03 (27.97) 90.89 (30.4)** 104.48 (26.18)£
Step length (m) 0.62 (0.15) 0.62 (0.16) 0.64 (0.16)† 0.46 (0.15) 0.49 (0.18)** 0.57 (0.16)£
Step time (s) 0.55 (0.14) 0.57 (0.17) 0.54 (0.14) 0.83 (0.32) 0.75 (0.28) 0.62 (0.18)***
Step width (m) 0.13 (0.05) 0.13 (0.04) 0.12 (0.04) 0.14 (0.07) 0.14 (0.07) 0.12 (0.06)
Stance time (% GC) 64.32 (4.17) 64.58 (4.83) 63.55 (4.6)† 70.01 (5.94) 68.76 (6.34) 65.46 (4.12)***
Double supp. time (% GC) 29.1 (8.22) 29.4 (9.66) 28.12 (8.12)† 40.53 (12.23) 37.76 (12.86) 31.25 (8.34)***
Table 5 Mean and  (SD) of  the different indices of  the PERSEPP HRQoL questionnaire for  the non-respondent 
and respondent groups at Pre 1, Pre 2 and Post 1
The italic values correspond statistical significant differences
* p < 0.05 Pre 2 versus Post 2
** p < 0.01 Pre 1 and Pre 2 versus Pre 1 and Post 2
*** p < 0.01 Post 1 versus Post 2
+  p 0.01 Pre 1 versus Post 2
†  p < 0.05 Pre 1 versus Post 2
‡  p < 0.05 Pre 1 and Pre 2 versus Post 1 and Post 2
PERSEPP (%) (items) Non-respondent Respondent
Pre 1 Pre 2 Post 1 Post 2 Pre 1 Pre 2 Post 1 Post 2
Overall (33) 63.1 (17.1) 62.5 (16.6) 66.3 (17.6) 68.2 (18.6)* 60.9 (15.1) 62.4 (18.2) 66.4 (18.3) 70.6 (18.5)+
Social support (5) 85.5 (15.3) 85.5 (12.7) 87.7 (12.4) 87.9 (12.9) 91.2 (10.7) 88.8 (23.3) 87.2 (24.6) 89.1 (24.6)
Relationship dif. (9) 54.8 (23.8) 55.5 (24.4) 62.1 (23.1) 60.9 (22.8) 46.4 (20) 53.1 (23.9) 51.9 (26.7) 64.1 (25)†
Fatigue (4) 43 (30.6) 43.6 (28.7) 48.2 (32.4) 47.6 (34.1) 44.6 (32.7) 45 (31.7) 63.1 (32.7)‡ 66.2 (34)‡
State of mind and sleep disor. (7) 64.9 (24.8) 64 (28.8) 65.5 (27.7) 67.8 (28.8) 59.2 (25) 65.1 (22.7) 72.3 (24) 73.5 (23.5)
Time perspective (8) 59.7 (21.7) 58.1 (21.6) 62 (25.3) 66.7 (24.6)* 58 (23.3) 56 (23.1) 63.5 (23.3) 66.4 (21.3)
Relapse (15) 50.9 (26.1) 53.5 (23.9) 56.5 (25.8) 56.9 (30.5) 42 (19.2) 42.1 (19.9) 45.3 (16.7) 52.7 (22.4)
Modules
Coping (8) 59.1 (20.5) 58.8 (20.5) 59.7 (20.8) 59.2 (20.6) 57.8 (15.8) 56.7 (17.2) 59.4 (22.2) 60 (21.2)
Symptoms (20) 56.2 (19) 56.8 (18.9) 58.9 (19.3)** 64.1 (19.2)** 50.8 (14.9) 51 (17.8) 61 (14.1)‡ 60.1 (18.2)‡
Treatment (5) 86.4 (15.5) 80.8 (21.3) 79.8 (18.9) 87.2 (14.7)*** 87 (17.6) 71.3 (36.4) 84 (16.5) 89.1 (11.9)
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our results corroborate with these studies where 30  % of 
patients with MS surpass 25 % of their baseline gait velocity. 
This result suggests the representativeness of our sample.
Considering that an improvement in walking or func-
tioning capacities may encompass several objectives (e.g., 
velocity, endurance, dexterity, comfort), recent studies 
took into account other tests related to MS symptoms 
(e.g., gait, arm function, fatigue) and found that fampri-
dine may impact on capacities beyond walking function 
(Allart et al. 2015; Pavsic et al. 2015). Allart et al. (2015) 
found that 74  % of patients with MS could potentially 
benefit in some way from fampridine. This was particu-
larly true for fast walkers who completed the T25FW in 
less than 8 s.
From the perspectives of gait and HRQoL, even after 
classifying patients into non-respondent and respondent 
groups, we found an improvement. However, large effect 
sizes for different spatiotemporal gait parameters and 
HRQoL indices were found for the respondent group. 
Furthermore, the respondent group surpassed the thresh-
old of Minimally Important Clinical Difference (MICD) 
reported by Coleman et al. (2012) (i.e., for walking veloc-
ity d  =  0.49). In spite of this fact, the non-respondent 
group was nearly twice as fast as the respondent group 
and should not be selected for fampridine treatment. As 
suggested by a previous study (Allart et  al. 2015), fast 
walkers seem to benefit less from fampridine based on 
walking velocity as a unique point of view. It is important 
to bear in mind that, even in this non-respondent group, 
gait velocity was still impaired when compared with nor-
mative values. Indeed, the walking velocity assessed in 
the fast condition in this study for the non-respondent 
group corresponds to the velocity of a group of women 
(n = 5013) aged 10 years more and at their self-selected 
velocity as reported in the Bohannon and Andrews meta-
analysis (Bohannon 2006).
Taking into consideration HRQoL, significant medium 
effects were found for all patients with MS. Both groups 
of non-respondents and respondents presented quite 
similar values at baseline and after fampridine for all 
indices (no significant difference between groups). How-
ever, the contribution of sub-indices to the Overall index 
seems different between groups. Indices with a signifi-
cant difference in the respondent group were Fatigue and 
Relationship difficulties. These indices seem more related 
to physical components (see the items of PERSEPP 
Baroin et  al. 2013), suggesting an association with gait 
improvement on the basis of spatiotemporal parame-
ters. In more detail, the Fatigue index is related to tired-
ness levels and the rest time of a patient. The respondent 
group showed the most improvement for this index and 
scored 18–22 percentage points more than the baseline, 
unlike the non-respondent group which still scored the 
same value as the baseline. It is probable that fampridine 
has an important role in fatigue as previously suggested 
in a study which demonstrated a decrease in general 
fatigue intensity after fampridine (Allart et al. 2015). The 
second index, Relationship difficulties, concerns more 
specifically the interactions with others (work, family, 
and partner/spouse). Improvement in walking velocity 
(even if it still very low in the respondent group) is one 
of the best predictors of a person’s independence (Fritz 
and Lusardi 2009) and related to fall risk (Hars et al. 2013; 
Cattaneo et al. 2002). This improvement is noted at Post 
2 (21 days after fampridine) and it is only after some time 
with gait improvement that patients are able to observe a 
change in their social lives.
The non-respondent group in turn showed improve-
ment in the Time perspective index. This index cor-
responds to a view which integrates the totality of the 
individual’s perspective of his past, present and future at 
any given time (Zimbardo and Boyd 1999). Time perspec-
tive seems associated with cognitive functioning (Ernst 
et al. 2014) or depressive tendencies (Baroin et al. 2013), 
which may both be modulated by fampridine.
To finish, it seems that there is no convincing clinical 
profile of patients’ responsiveness to fampridine with our 
study. The EDSS was the only clinical factor which was 
significantly different between the non-respondent and 
respondent groups. The only difference was that indi-
viduals in the non-respondent group were categorized as 
“Disability precludes full daily activities” whereas those 
in the respondent group were categorized as “Assistance 
required to walk”. This difference was not found in previ-
ous studies which did not identify any predictive factors 
for effectiveness (Allart et al. 2015; Goodman et al. 2009, 
2010) in spite of the EDSS mean values which had in all 
cases a worse value in the respondent group.
This study could contribute to knowledge of fampri-
dine’s subjective global effect (i.e., physical, emotional, 
mental, roles and social functioning) in patients with MS. 
For this purpose, a disease-specific HRQoL questionnaire 
with a good reliability was employed. This specific ques-
tionnaire should have the advantage of focusing on par-
ticular health problems related to MS and might be more 
sensitive to the detection and quantification of changes 
related to the disease.
However, this prospective non-randomized study 
presents several limitations. First of all, the absence of 
a placebo group might have overestimated the fampri-
dine effect in HRQoL. However, in phase III fampridine 
clinical trials, the percentage of patients who met the 
responder criterion in the placebo group was around 
9 % in motor and cognitive outcomes suggesting a weak 
placebo effect (Goodman et al. 2010; Jensen et al. 2014). 
Secondly, despite the effort to use a specific validated 
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HRQoL questionnaire, at the moment there is no thresh-
old that we could consider as MICD for the PERSEPP. 
This should be suitable for the non-respondent group 
whose medium effect sizes were found. Third, in spite 
of the importance of the HRQoL, it is important to be 
aware of the bias related with self-report questionnaires, 
which can be influenced by memory deficits or the desire 
to please the health-care provider. To finish, as with the 
majority of studies, the fampridine effect was assessed 
during a short distance test (i.e., the T25FW found for 
several studies). Although its applicability in clinical 
practice, this gait test represents neither the range of eve-
ryday gait activities (e.g., walking long distances or up 
and down stairs) nor the participations that result from 
the walking activity (e.g., going for a walk, shopping, 
social activities). A recent European multicenter study 
found that long walking tests were more appropriate 
than short walking ones in detecting clinically meaning-
ful improvement (Baert et al. 2014). The choice of a gait 
tests may influence the responder group allocation. The 
encouraging results of the fampridine on HRQoL should 
be confirmed by a larger randomized double blind pla-
cebo controlled trials.
In conclusion, our study showed that patients with 
MS improved their HRQoL after fampridine, suggest-
ing a real benefit in their lives. Both non-respondent 
and respondent groups improved their HRQoL although 
important effects were seen only in the respondent 
group. To finish, the contributions to overall HRQoL 
improvement seem different after fampridine between 
the non-respondent and respondent groups. The Fatigue 
and Relationship difficulties indices contributed sig-
nificantly to overall improvement for HRQoL in the 
respondent group whereas, in the non-respondent group, 
it was Time perspective that seemed to better contribute 
to overall improvement in HRQoL.
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